Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): An extension of the dietary fat hypothesis of breast cancer

Medical Hypotheses

Volumn 52, Issue 4, 1999, Pages 291-292

  Harris, R E ^a   Robertson, F M ^a   Abou Issa, H M ^a   Farrar, W B ^a   Brueggemeier, R ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESSENTIAL FATTY ACID; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; VASCULOTROPIN;

BREAST CANCER; BREAST CARCINOGENESIS; ENZYME REGULATION; FAT INTAKE; GENE INDUCTION; MODEL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SHORT SURVEY;

EID: 0032981027     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1998.0009     Document Type: Article

References (15)

1. Harris R. E., Namboodiri K. K., Stellman S. D., Wynder E. L. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med. 24:1995;119-120.
2. Harris R. E., Namboodiri K. K., Farrar W. B. Epidemiologic study of non-steroidal anti-inflammatory drugs and breast cancer. Oncol Reports. 2:1995;591-592.
3. Harris R. E., Namboodiri K. K., Farrar W. B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 7:1996;203-205.
4. Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 5:1994;138-146.
5. Herschman H. R. Regulation of prostaglandin synthase-1and prostaglandin synthase-2. Cancer Metas Rev. 13:1994;241-256.
6. Parrett M. L., Harris R. E., Joarder F. S., Ross M. S., Clausen K. P., Robertson F. M. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol. 10:1997;503-507.
7. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol). 231:1971;232-235.
8. Marnett L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52:1992;5575-5589.
9. Zhao Y., Agarwal V. R., Mendelson C. R., Simpson E. R. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 137:1996;5739-5742.
10. Ben-Av P., Crofford L. J., Wilder R. L., Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by Prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372:1995;83-87.
11. Wu K. K. Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles [Review]. J Lab Clin Med. 128:1996;242-245.
12. Karmali R. A., Adams L., Trout J. R. Plant and marine n-3 fatty acids inhibit experimental metastasis of rat mammary adenocarinoma cells. Prostaglandins Leukot Essent Fatty Acids. 48:1993;309-314.
13. Ramchurren N., Karmali R. A. Effects of gamma-linolenic and dihomo-gamma-linolenic fatty acids on 7.12 dimethylbenz(alpha)anthracene mammary tumors in rats. Prostaglandins Leukot Essent Fatty Acids. 53:1995;95-101.
14. Mitchell J. A., Akarasereenont P., Thiemermann C., Flower R. J., Vane J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 90:1994;11693-11697.
15. Harris R. E., Kasbari S., Farrar W. B. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Reports. 6:1999;71-73.